Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Current Leases (2019 - 2023)

Rein Therapeutics (RNTX) has disclosed Current Leases for 5 consecutive years, with $48000.0 as the latest value for Q4 2023.

  • Quarterly Current Leases rose 45.45% to $48000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $48000.0 through Dec 2023, up 45.45% year-over-year, with the annual reading at $48000.0 for FY2023, 45.45% up from the prior year.
  • Current Leases for Q4 2023 was $48000.0 at Rein Therapeutics, up from $33000.0 in the prior quarter.
  • The five-year high for Current Leases was $512000.0 in Q3 2020, with the low at $33000.0 in Q4 2022.
  • Average Current Leases over 5 years is $242875.0, with a median of $115500.0 recorded in 2022.
  • The sharpest move saw Current Leases tumbled 81.84% in 2021, then skyrocketed 45.45% in 2023.
  • Over 5 years, Current Leases stood at $446000.0 in 2019, then grew by 14.8% to $512000.0 in 2020, then crashed by 81.84% to $93000.0 in 2021, then tumbled by 64.52% to $33000.0 in 2022, then surged by 45.45% to $48000.0 in 2023.
  • According to Business Quant data, Current Leases over the past three periods came in at $48000.0, $33000.0, and $67000.0 for Q4 2023, Q4 2022, and Q3 2022 respectively.